- Home
- HLP vs NSPR Comparison
HLP vs NSPR Comparison
Compare HLP & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- NSPR
- Stock Information
- Founded
- HLP 2021
- NSPR 2005
- Country
- HLP China
- NSPR United States
- Employees
- HLP N/A
- NSPR N/A
- Industry
- HLP Industrial Machinery/Components
- NSPR Medical/Dental Instruments
- Sector
- HLP Industrials
- NSPR Health Care
- Exchange
- HLP Nasdaq
- NSPR Nasdaq
- Market Cap
- HLP 65.3M
- NSPR 75.1M
- IPO Year
- HLP 2023
- NSPR N/A
- Fundamental
- Price
- HLP $0.68
- NSPR $2.44
- Analyst Decision
- HLP
- NSPR Strong Buy
- Analyst Count
- HLP 0
- NSPR 2
- Target Price
- HLP N/A
- NSPR $4.50
- AVG Volume (30 Days)
- HLP 152.7K
- NSPR 385.7K
- Earning Date
- HLP 05-12-2025
- NSPR 08-05-2025
- Dividend Yield
- HLP N/A
- NSPR N/A
- EPS Growth
- HLP N/A
- NSPR N/A
- EPS
- HLP N/A
- NSPR N/A
- Revenue
- HLP $14,105,620.00
- NSPR $7,027,000.00
- Revenue This Year
- HLP N/A
- NSPR $4.85
- Revenue Next Year
- HLP N/A
- NSPR $113.47
- P/E Ratio
- HLP N/A
- NSPR N/A
- Revenue Growth
- HLP N/A
- NSPR 8.49
- 52 Week Low
- HLP $0.63
- NSPR $1.99
- 52 Week High
- HLP $2.13
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- HLP 30.74
- NSPR 54.16
- Support Level
- HLP $0.72
- NSPR $2.12
- Resistance Level
- HLP $0.78
- NSPR $2.46
- Average True Range (ATR)
- HLP 0.08
- NSPR 0.16
- MACD
- HLP -0.01
- NSPR 0.01
- Stochastic Oscillator
- HLP 3.67
- NSPR 73.33
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.